Abstract:Obesity has been linked with increased incidence and worse outcomes of at least 13 human cancers. For other cancers, our understanding of their relationship with obesity is more nebulous, with contradictory observations from different studies. An example is lung cancer. Central or visceral obesity is defined as accumulation of excess or abnormal fat in body that is harmful to its health. But in lung cancer, overweight and obesity, as defined by body mass index (BMI), is associated with reduced cancer risk and longer survival after treatment by surgery. In addition, some studies suggest that lung cancer in obese patients responds better to treatment with immune checkpoint inhibitors (ICIs) than in the non-obese. Apart from interesting biological questions, this "obesity paradox" presents practical issues in cancer prevention and clinical management, starting with the fundamental question of whether weight loss should be recommended in these contexts. Our investigations suggest that the incongruence between the observed benefits of obesity and its expected detrimental nature is likely the result of two main confounding factors in lung cancer studies. The first major confounding factor which we noticed is that certain commonly used medications have a secondary anti-cancer effect that is obesity-dependent. This is exemplified by the anti-diabetic metformin, which was prescribed 90 million times in 2021 in the US. We found that metformin use was associated with decreased likelihood of recurrence of early-stage lung cancer after resection, but only in overweight/obese patients (BMI > 25). Additionally, in late-stage cancer, metformin use by such patients correlated with a decrease in immune checkpoint molecules in their tumors, whereas an opposite effect of metformin use was seen in patients with lower BMI ( 90% of lung cancer. A retrospective analysis of more than 500 such patients who were treated with ICIs in our institution showed that this is indeed the case. Consistent with our mouse studies, disease progression among the ICI-treated patients was slowed by metformin in only overweight/obese patients. This set of observations raises the possibility that obesity-dependent anti-cancer effects similar to metformin's may exist for other commonly used drugs, especially those impacting cellular metabolism. Indeed, we found this to be the case for statins. In one study of approximately 600 early-stage non-small cell lung cancer patients who had resective surgery at our institution, use of statins was associated with longer recurrence-free survival in overweight/obese but not other patients. Our observations on confounding by metformin and statins show that the use of such medications has to be accounted for if the effect of obesity on cancer behavior is to be estimated in clinical or epidemiological studies. The other major confounding factor is the use of BMI as a measure of obesity. The validity of BMI as a sole measure of obesity is increasingly being questioned because it does not accurately capture body fat content or its heterogeneity and distribution, which are also biologically relevant. We find this to be the case in lung cancer as well. In a case-control study for which we used routine computerized tomographic (CT) images to accurately measure the body's fat content, we found that patients with early-stage lung cancer have more fat, but not higher BMI, than subjects without lung cancer but at high risk for the disease. Correspondingly, in mice, we and others have found that diet-induced obesity increases lung carcinogenesis by urethane and oncogenic Kras. This accelerated tumor growth is accompanied by enhanced suppressor leukocyte pools in the lung. To test if compromised immune surveillance could underpin the increased risk of cancer seen in obese patients, we characterized the leukocytes recovered from bronchoalveolar lavage fluids of subjects determined obese and non-obese by CT image analysis. Consistent with our hypothesis, and with our assessment of the lung immune cells of obese and non-obese mice, obese subject -Abstract Truncated-

Chronic obesity does not alter cancer survival in mice

Obesity Promotes Marrow-Derived Myeloid Cell Accumulation while Exercise Reduces Proliferative Signaling in Colon Cancer

Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence

Abstract SY38-02: Clinical investigations of obesity in cancer: BMI and other confounders

Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk

Abstract SY38-01: Diverse effects of obesity on cancer immunology and therapy: Both the good and the bad

Effects of High‐fat Diet‐induced Adipokines and Cytokines on Colorectal Cancer Development

Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice

Disentangling the obesity paradox in upper gastrointestinal cancers: Weight loss matters more than body mass index

A Combined Effect of Expression Levels of Obesity-Related Genes and Clinical Factors on Cancer Survival Rate

High-fat diet-fed ovariectomized mice are susceptible to accelerated subcutaneous tumor growth potentially through adipose tissue inflammation, local insulin-like growth factor release, and tumor associated macrophages

Abstract C048: Obesity transforms the gut microbiome to invoke a cancer permissive state

Abstract 3982: Evaluating the effects of obesity on immune responses in renal tumors

Body Weight Correlates with Molecular Variances in Cancer Patients

High-Fat Diet-Induced Obese Effects of Adipocyte-Specific CXCR2 Conditional Knockout in the Peritoneal Tumor Microenvironment of Ovarian Cancer

Obesity paradox: is a high body mass index positively influencing survival outcomes in gynecological cancers? A systematic review and meta-analysis

Abstract 2190: Transcriptomic signatures of obesity-driven colon cancer: A multi-species transdisciplinary approach

High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer

A triad of complete dorsal pancreatic agenesis, pancake kidney and bicornuate uterus. An association or an incidental finding: first case in literature.

Host obesity alters the ovarian tumor immune microenvironment and impacts response to standard of care chemotherapy

The obesity paradox in multiple myeloma: A report from Multiple Myeloma Research Foundation (MMRF) dataset